FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4256658051> ?p ?o ?g. }

• W4256658051 abstract "Abstract Background: Trastuzumab-induced cardiotoxicity (TIC) can lead to early discontinuation of adjuvant therapy, however there is limited evidence on long-term survival outcomes in patients with operable human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) experiencing treatment interruption or discontinuation. Methods: The primary objective of the study was to evaluate disease-free survival (DFS) in non-metastatic, HER2-positive, female BC patients who experienced treatment interruption or early discontinuation of trastuzumab therapy. Clinical and histopathological data were collected on 400 patients at The Ohio State University, an NCI-designated comprehensive cancer center between January 2005 and December 2015. Treatment interruption was defined as any delay of ≥2 weeks during trastuzumab therapy, including permanent cessation prior to completing planned therapy. TIC was defined as LVEF <50% or >15 points decline from baseline as evaluated by 2D echocardiogram after initiation of (neo) adjuvant therapy. DFS was defined as the time from diagnosis to first recurrence (loco-regional or distant recurrence) including second primary BC or death. Overall survival (OS) was defined as the time from diagnosis to death or last known follow up. OS/DFS estimates were generated using Kaplan-Meier methods and compared using Log-rank tests. Cox proportional hazard models were used to calculate adjusted hazard ratios (aHR) for OS/DFS. Results: A total of 369 patients received trastuzumab therapy; 106 (29%) patients experienced treatment interruption at least once and 42 (11%) permanently discontinued trastuzumab prior to completing planned therapy. TIC was the most common reason for interruption (66 patients, 62%). The median duration of trastuzumab in patients with treatment interruption was 11.3 months (range: 0.5-16.9) with 24 (23%) patients receiving ≤6 months of therapy. Patients with any treatment interruption had worse DFS (aHR: 4.9, p<0.001) and OS (aHR: 2.4, p=0.058) after adjusting for age, stage, grade, ER, node status and TIC. Conclusions : Treatment interruption or early discontinuation of trastuzumab therapy in early HER2-positive BC, most often from TIC, is an independent prognostic marker for worse DFS and OS in operable HER2-positive BC. Future prospective studies should consider targeting at-risk populations and optimizing cardiac function to avoid interruption in trastuzumab therapy." @default.
• W4256658051 created "2022-05-12" @default.
• W4256658051 creator A5009612327 @default.
• W4256658051 creator A5016612817 @default.
• W4256658051 creator A5030631262 @default.
• W4256658051 creator A5030653735 @default.
• W4256658051 creator A5038225493 @default.
• W4256658051 creator A5049785882 @default.
• W4256658051 creator A5056531003 @default.
• W4256658051 creator A5060904459 @default.
• W4256658051 creator A5064885323 @default.
• W4256658051 creator A5065015589 @default.
• W4256658051 creator A5067587535 @default.
• W4256658051 creator A5069711994 @default.
• W4256658051 creator A5072335237 @default.
• W4256658051 creator A5080607677 @default.
• W4256658051 creator A5086903918 @default.
• W4256658051 date "2020-08-18" @default.
• W4256658051 modified "2023-09-27" @default.
• W4256658051 title "Clinical Impact of Interruption in Adjuvant Trastuzumab Therapy in Patients with Operable HER-2 Positive Breast Cancer" @default.
• W4256658051 doi "https://doi.org/10.21203/rs.3.rs-60091/v1" @default.
• W4256658051 hasPublicationYear "2020" @default.
• W4256658051 type Work @default.
• W4256658051 citedByCount "0" @default.
• W4256658051 crossrefType "posted-content" @default.
• W4256658051 hasAuthorship W4256658051A5009612327 @default.
• W4256658051 hasAuthorship W4256658051A5016612817 @default.
• W4256658051 hasAuthorship W4256658051A5030631262 @default.
• W4256658051 hasAuthorship W4256658051A5030653735 @default.
• W4256658051 hasAuthorship W4256658051A5038225493 @default.
• W4256658051 hasAuthorship W4256658051A5049785882 @default.
• W4256658051 hasAuthorship W4256658051A5056531003 @default.
• W4256658051 hasAuthorship W4256658051A5060904459 @default.
• W4256658051 hasAuthorship W4256658051A5064885323 @default.
• W4256658051 hasAuthorship W4256658051A5065015589 @default.
• W4256658051 hasAuthorship W4256658051A5067587535 @default.
• W4256658051 hasAuthorship W4256658051A5069711994 @default.
• W4256658051 hasAuthorship W4256658051A5072335237 @default.
• W4256658051 hasAuthorship W4256658051A5080607677 @default.
• W4256658051 hasAuthorship W4256658051A5086903918 @default.
• W4256658051 hasBestOaLocation W42566580511 @default.
• W4256658051 hasConcept C121608353 @default.
• W4256658051 hasConcept C126322002 @default.
• W4256658051 hasConcept C141071460 @default.
• W4256658051 hasConcept C143998085 @default.
• W4256658051 hasConcept C207103383 @default.
• W4256658051 hasConcept C2776694085 @default.
• W4256658051 hasConcept C2777863537 @default.
• W4256658051 hasConcept C2777982462 @default.
• W4256658051 hasConcept C2778233292 @default.
• W4256658051 hasConcept C2778715236 @default.
• W4256658051 hasConcept C2779786085 @default.
• W4256658051 hasConcept C44249647 @default.
• W4256658051 hasConcept C50382708 @default.
• W4256658051 hasConcept C530470458 @default.
• W4256658051 hasConcept C71924100 @default.
• W4256658051 hasConceptScore W4256658051C121608353 @default.
• W4256658051 hasConceptScore W4256658051C126322002 @default.
• W4256658051 hasConceptScore W4256658051C141071460 @default.
• W4256658051 hasConceptScore W4256658051C143998085 @default.
• W4256658051 hasConceptScore W4256658051C207103383 @default.
• W4256658051 hasConceptScore W4256658051C2776694085 @default.
• W4256658051 hasConceptScore W4256658051C2777863537 @default.
• W4256658051 hasConceptScore W4256658051C2777982462 @default.
• W4256658051 hasConceptScore W4256658051C2778233292 @default.
• W4256658051 hasConceptScore W4256658051C2778715236 @default.
• W4256658051 hasConceptScore W4256658051C2779786085 @default.
• W4256658051 hasConceptScore W4256658051C44249647 @default.
• W4256658051 hasConceptScore W4256658051C50382708 @default.
• W4256658051 hasConceptScore W4256658051C530470458 @default.
• W4256658051 hasConceptScore W4256658051C71924100 @default.
• W4256658051 hasLocation W42566580511 @default.
• W4256658051 hasLocation W42566580512 @default.
• W4256658051 hasLocation W42566580513 @default.
• W4256658051 hasOpenAccess W4256658051 @default.
• W4256658051 hasPrimaryLocation W42566580511 @default.
• W4256658051 hasRelatedWork W141138677 @default.
• W4256658051 hasRelatedWork W2029518877 @default.
• W4256658051 hasRelatedWork W2100224620 @default.
• W4256658051 hasRelatedWork W2321907265 @default.
• W4256658051 hasRelatedWork W2420535504 @default.
• W4256658051 hasRelatedWork W2955988240 @default.
• W4256658051 hasRelatedWork W2969515167 @default.
• W4256658051 hasRelatedWork W2969537103 @default.
• W4256658051 hasRelatedWork W3047621048 @default.
• W4256658051 hasRelatedWork W2199341048 @default.
• W4256658051 isParatext "false" @default.
• W4256658051 isRetracted "false" @default.
• W4256658051 workType "article" @default.